S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Is This The Collapse of Icahn Enterprises ?
Laser breakthrough could send stock soaring 2,467% (Ad)
20 Best Healthcare Dividend Stocks to Invest in
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
BREAKING: Tiny biotech successfully treats blindness (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
BREAKING: Tiny biotech successfully treats blindness (Ad)
What Does the Airbnb Guidance Drop Say About Travel Demand?
Europe sees inflation drop to 6.1%, but real relief for consumers will take months
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Is This The Collapse of Icahn Enterprises ?
Laser breakthrough could send stock soaring 2,467% (Ad)
20 Best Healthcare Dividend Stocks to Invest in
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
BREAKING: Tiny biotech successfully treats blindness (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
BREAKING: Tiny biotech successfully treats blindness (Ad)
What Does the Airbnb Guidance Drop Say About Travel Demand?
Europe sees inflation drop to 6.1%, but real relief for consumers will take months
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Is This The Collapse of Icahn Enterprises ?
Laser breakthrough could send stock soaring 2,467% (Ad)
20 Best Healthcare Dividend Stocks to Invest in
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
BREAKING: Tiny biotech successfully treats blindness (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
BREAKING: Tiny biotech successfully treats blindness (Ad)
What Does the Airbnb Guidance Drop Say About Travel Demand?
Europe sees inflation drop to 6.1%, but real relief for consumers will take months
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Is This The Collapse of Icahn Enterprises ?
Laser breakthrough could send stock soaring 2,467% (Ad)
20 Best Healthcare Dividend Stocks to Invest in
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
BREAKING: Tiny biotech successfully treats blindness (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
BREAKING: Tiny biotech successfully treats blindness (Ad)
What Does the Airbnb Guidance Drop Say About Travel Demand?
Europe sees inflation drop to 6.1%, but real relief for consumers will take months
NASDAQ:ACON

Aclarion (ACON) Competitors

$1.03
+0.04 (+4.04%)
(As of 06/1/2023 ET)
Compare
Today's Range
$0.89
$1.07
50-Day Range
$0.59
$1.28
52-Week Range
$0.38
$2.37
Volume
325,739 shs
Average Volume
1.23 million shs
Market Capitalization
$8.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

ACON vs. FRES, ANPC, OPGN, AMS, CNTG, PMD, REUN, NURO, CYCC, and AGLE

Should you be buying Aclarion stock or one of its competitors? The main competitors of Aclarion include Fresh2 Group (FRES), Fresh2 Group (ANPC), OpGen (OPGN), American Shared Hospital Services (AMS), Centogene (CNTG), Psychemedics (PMD), Reunion Neuroscience (REUN), NeuroMetrix (NURO), Cyclacel Pharmaceuticals (CYCC), and Aeglea BioTherapeutics (AGLE). These companies are all part of the "medical" sector.

Aclarion vs.

Aclarion (NASDAQ:ACON) and Fresh2 Group (NASDAQ:FRES) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, community ranking, analyst recommendations and profitability.

Aclarion received 1 more outperform votes than Fresh2 Group when rated by MarketBeat users.

CompanyUnderperformOutperform
AclarionOutperform Votes
1
100.00%
Underperform Votes
No Votes
Fresh2 GroupN/AN/A

Aclarion currently has a consensus target price of $3.00, indicating a potential upside of 191.26%. Given Aclarion's higher probable upside, research analysts clearly believe Aclarion is more favorable than Fresh2 Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aclarion
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Fresh2 Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

2.0% of Aclarion shares are held by institutional investors. Comparatively, 45.8% of Fresh2 Group shares are held by institutional investors. 22.1% of Aclarion shares are held by company insiders. Comparatively, 26.2% of Fresh2 Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Aclarion had 2 more articles in the media than Fresh2 Group. MarketBeat recorded 2 mentions for Aclarion and 0 mentions for Fresh2 Group. Aclarion's average media sentiment score of 0.89 beat Fresh2 Group's score of 0.00 indicating that Aclarion is being referred to more favorably in the media.

Company Overall Sentiment
Aclarion Positive
Fresh2 Group Neutral

Fresh2 Group has a net margin of 0.00% compared to Aclarion's net margin of -12,583.55%.

Company Net Margins Return on Equity Return on Assets
Aclarion -12,583.55% N/A -206.46%
Fresh2 Group N/A N/A N/A

Aclarion has higher earnings, but lower revenue than Fresh2 Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aclarion$60.44 thousand133.96-$7.61 millionN/AN/A
Fresh2 Group$1.75 million2.34-$14.77 millionN/AN/A

Summary

Aclarion beats Fresh2 Group on 7 of the 12 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACON vs. The Competition

MetricAclarionMedical laboratories IndustryMedical SectorNASDAQ Exchange
Market Cap$8.10M$1.76B$4.55B$5.82B
Dividend YieldN/A2.82%2.43%6.15%
P/E RatioN/A9.32144.6414.55
Price / Sales133.9654.723,646.3895.79
Price / CashN/A7.5091.29108.31
Price / Book4.482.825.167.27
Net Income-$7.61M-$110.02M$117.98M$175.81M
7 Day Performance74.58%1.80%2.09%1.59%
1 Month Performance56.23%-0.12%4.62%4.74%
1 Year Performance-15.57%-0.32%21.44%0.11%

Aclarion Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FRES
Fresh2 Group
0 of 5 stars
$4.39
-3.9%
N/AN/A$4.26M$1.75M0.00N/AGap Up
ANPC
Fresh2 Group
0 of 5 stars
$4.37
-5.4%
N/A-21.7%$4.24M$1.75M0.0086
OPGN
OpGen
1.6945 of 5 stars
$0.71
flat
$2.13
+199.3%
+11.0%$3.91M$2.61M-0.0591Positive News
AMS
American Shared Hospital Services
0 of 5 stars
$2.82
-3.4%
N/AN/A$17.52M$19.82M14.10N/AAnalyst Report
High Trading Volume
CNTG
Centogene
2.3174 of 5 stars
$0.81
+1.2%
$3.75
+362.4%
-68.2%$21.96M$47.47M-0.34660Gap Down
PMD
Psychemedics
0 of 5 stars
$4.87
-1.0%
N/A-23.6%$27.86M$25.24M-18.04139Negative News
REUN
Reunion Neuroscience
2.0107 of 5 stars
$0.70
flat
$8.25
+1,078.6%
N/A$8.20M$3.88M0.00N/ANews Coverage
Gap Up
NURO
NeuroMetrix
0 of 5 stars
$1.05
+1.0%
N/A-76.0%$8.19M$8.26M-1.5123Analyst Report
Gap Up
CYCC
Cyclacel Pharmaceuticals
1.5895 of 5 stars
$0.64
-3.0%
$8.00
+1,141.9%
-45.5%$8.08MN/A-0.332,018Analyst Report
AGLE
Aeglea BioTherapeutics
1.8241 of 5 stars
$0.13
-7.2%
$1.88
+1,352.4%
-91.2%$8.44M$2.33M-0.15101

Related Companies and Tools

This page (NASDAQ:ACON) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -